Scienceargenx says efgartigimod met main goal in myositis trial

Belgian-Dutch immunology company argenx said its drug efgartigimod achieved the primary endpoint in a late-stage trial involving adults with autoimmune myositis, with a significant improvement in disease activity.

argenxefgartigimodautoimmune myositis

RReuters★★☆☆☆2026-08-17 08:10Original